• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.经衣壳修饰的重组 AAV2 载体高效转导人源单核细胞来源的树突状细胞。
Vaccine. 2012 Jun 6;30(26):3908-17. doi: 10.1016/j.vaccine.2012.03.079. Epub 2012 Apr 10.
2
Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.对腺相关病毒2型(AAV2)衣壳特定丝氨酸、苏氨酸或赖氨酸残基进行生物工程改造可提高其在体外和体内的转导效率。
Hum Gene Ther Methods. 2013 Apr;24(2):80-93. doi: 10.1089/hgtb.2012.194. Epub 2013 Mar 15.
3
Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?优化重组腺相关病毒 2(AAV2)载体的衣壳:最后的门槛?
PLoS One. 2013;8(3):e59142. doi: 10.1371/journal.pone.0059142. Epub 2013 Mar 19.
4
Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo.表面暴露赖氨酸残基的定点诱变可改善AAV2而非AAV8载体在小鼠肝细胞体内的转导。
Hum Gene Ther Methods. 2015 Dec;26(6):211-20. doi: 10.1089/hgtb.2015.115. Epub 2015 Oct 27.
5
Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy.用于基于树突状细胞的癌症免疫治疗的AAV6载体的合理设计衣壳和转基因盒。
Immunol Cell Biol. 2014 Feb;92(2):116-23. doi: 10.1038/icb.2013.74. Epub 2013 Nov 12.
6
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.下一代腺相关病毒2型载体:酪氨酸位点的点突变可实现低剂量下的高效转导。
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7827-32. doi: 10.1073/pnas.0802866105. Epub 2008 May 29.
7
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.2型腺相关病毒(AAV2)衣壳特异性细胞毒性T淋巴细胞在体内仅消除共表达AAV2衣壳的载体转导细胞。
J Virol. 2007 Jul;81(14):7540-7. doi: 10.1128/JVI.00529-07. Epub 2007 May 2.
8
Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.嵌合衣壳蛋白影响单倍体腺相关病毒载体的转导效率。
Viruses. 2019 Dec 9;11(12):1138. doi: 10.3390/v11121138.
9
Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.2型腺相关病毒(AAV2)衣壳基因的插入诱变及靶向替代细胞表面受体的AAV2载体的产生。
Hum Gene Ther. 2001 Sep 20;12(14):1697-711. doi: 10.1089/104303401750476212.
10
High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.酪氨酸突变型AAV2载体对成纤维细胞和间充质干细胞的高效转导及其在细胞治疗中的潜在应用
Hum Gene Ther. 2010 Nov;21(11):1527-43. doi: 10.1089/hum.2010.005. Epub 2010 Oct 6.

引用本文的文献

1
Strategies to improve safety profile of AAV vectors.改善腺相关病毒载体安全性的策略。
Front Mol Med. 2022 Nov 1;2:1054069. doi: 10.3389/fmmed.2022.1054069. eCollection 2022.
2
Optimal trade-off control in machine learning-based library design, with application to adeno-associated virus (AAV) for gene therapy.基于机器学习的文库设计中的最优权衡控制,应用于腺相关病毒(AAV)基因治疗。
Sci Adv. 2024 Jan 26;10(4):eadj3786. doi: 10.1126/sciadv.adj3786. Epub 2024 Jan 24.
3
Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.腺相关病毒(AAV)作为基因治疗剂在肝细胞癌中的最新进展。
Virol J. 2024 Jan 12;21(1):17. doi: 10.1186/s12985-024-02286-1.
4
Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy.用于人类基因治疗的安全有效优化腺相关病毒载体开发的原理与策略
Mol Ther Nucleic Acids. 2023 May 17;32:949-959. doi: 10.1016/j.omtn.2023.05.014. eCollection 2023 Jun 13.
5
AAV Engineering for Improving Tropism to the Central Nervous System.用于改善对中枢神经系统嗜性的腺相关病毒工程
Biology (Basel). 2023 Jan 26;12(2):186. doi: 10.3390/biology12020186.
6
An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation.一种基于工程化腺相关病毒6型的疫苗通过直接靶向树突状细胞诱导高细胞溶解抗肿瘤活性并改善抗原呈递。
Mol Ther Oncolytics. 2019 Oct 7;15:166-177. doi: 10.1016/j.omto.2019.10.001. eCollection 2019 Dec 20.
7
Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes.重组腺相关病毒 (AAV) 1-rh10 血清型衣壳蛋白的翻译后修饰。
FEBS J. 2019 Dec;286(24):4964-4981. doi: 10.1111/febs.15013. Epub 2019 Aug 1.
8
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges.用慢病毒和 AAV 靶向小胶质细胞:最新进展和遗留挑战。
Neurosci Lett. 2019 Aug 10;707:134310. doi: 10.1016/j.neulet.2019.134310. Epub 2019 May 31.
9
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases.用于人类肝脏疾病基因治疗的新一代腺相关病毒载体。
Gastroenterol Clin North Am. 2019 Jun;48(2):319-330. doi: 10.1016/j.gtc.2019.02.005. Epub 2019 Apr 1.
10
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.用于靶向和提高腺相关病毒载体效力的衣壳修饰
Mol Ther Methods Clin Dev. 2019 Jan 26;12:248-265. doi: 10.1016/j.omtm.2019.01.008. eCollection 2019 Mar 15.

本文引用的文献

1
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.优化的 AAV3 血清型载体的开发:高效转导人肝癌细胞的机制。
Gene Ther. 2012 Apr;19(4):375-84. doi: 10.1038/gt.2011.105. Epub 2011 Jul 21.
2
Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy.腺相关病毒 (AAV) 载体激活 NF-κB 通路及其在免疫反应和基因治疗中的意义。
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3743-8. doi: 10.1073/pnas.1012753108. Epub 2011 Feb 14.
3
Recent developments in cancer vaccines.癌症疫苗的最新进展。
J Immunol. 2011 Feb 1;186(3):1325-31. doi: 10.4049/jimmunol.0902539.
4
Immunologic basis of vaccine vectors.疫苗载体的免疫学基础。
Immunity. 2010 Oct 29;33(4):504-15. doi: 10.1016/j.immuni.2010.10.004.
5
High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.利用缺乏多个表面暴露的酪氨酸的 AAV2 载体高效转导和纠正小鼠血友病 B。
Mol Ther. 2010 Dec;18(12):2048-56. doi: 10.1038/mt.2010.172. Epub 2010 Aug 24.
6
Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6.重组腺相关病毒血清型 6 对人单核细胞来源树突状细胞的优化转导。
Hum Gene Ther. 2010 Dec;21(12):1675-86. doi: 10.1089/hum.2010.087.
7
An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells.一种用于在昆虫Sf9细胞中高效生产重组腺相关病毒(rAAV)载体的诱导系统。
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5059-64. doi: 10.1073/pnas.0810614106. Epub 2009 Mar 11.
8
Heparin binding induces conformational changes in Adeno-associated virus serotype 2.肝素结合会诱导2型腺相关病毒的构象变化。
J Struct Biol. 2009 Mar;165(3):146-56. doi: 10.1016/j.jsb.2008.12.002. Epub 2008 Dec 13.
9
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.用重组腺相关病毒/人表皮生长因子受体2(rAAV/Her-2/neu)负载树突状细胞,以引发针对卵巢癌的强大细胞介导的主要组织相容性复合体I类限制免疫反应。
Viral Immunol. 2008 Dec;21(4):435-42. doi: 10.1089/vim.2008.0029.
10
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.酪氨酸突变型腺相关病毒血清型载体对小鼠视网膜的高效转导
Mol Ther. 2009 Mar;17(3):463-71. doi: 10.1038/mt.2008.269. Epub 2008 Dec 16.

经衣壳修饰的重组 AAV2 载体高效转导人源单核细胞来源的树突状细胞。

High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.

机构信息

Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL, USA.

出版信息

Vaccine. 2012 Jun 6;30(26):3908-17. doi: 10.1016/j.vaccine.2012.03.079. Epub 2012 Apr 10.

DOI:10.1016/j.vaccine.2012.03.079
PMID:22497875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3356484/
Abstract

Phosphorylation of surface-exposed tyrosine residues negatively impacts the transduction efficiency of recombinant AAV2 vectors. Pre-treatment of cells with specific cellular serine/threonine kinase inhibitors also significantly increased the transduction efficiency of AAV2 vectors. We reasoned that site-directed mutagenesis of surface-exposed serine residues might allow the vectors to evade phosphorylation and thus lead to higher transduction efficiency. Each of the 15 surface-exposed serine (S) residues was substituted with valine (V) residues, and the transduction efficiency of three of these mutants, S458V, S492V and S662V, was increased by up to ≈ 20-fold in different cell types. The S662V mutant was efficient in transducing human monocyte-derived dendritic cells (moDCs), a cell type not readily amenable to transduction by the conventional AAV vectors, and did not induce any phenotypic changes in these cells. Recombinant S662V-AAV2 vectors encoding a truncated human telomerase (hTERT) gene were generated and used to stimulate cytotoxic T cells (CTLs) against target cells. S662V-AAV2-hTERT vector-transduced DCs resulted in rapid, specific T-cell clone proliferation and generation of robust CTLs, which led to specific cell lysis of K562 cells. These studies suggest that high-efficiency transduction of moDCs by serine-modified AAV2 vectors is feasible, which supports the potential utility of these vectors for future human DCs vaccine studies.

摘要

表面暴露的酪氨酸残基的磷酸化会负向影响重组 AAV2 载体的转导效率。用特定的细胞丝氨酸/苏氨酸激酶抑制剂预处理细胞也显著提高了 AAV2 载体的转导效率。我们推测,表面暴露的丝氨酸残基的定点突变可能使载体逃避磷酸化,从而导致更高的转导效率。将 15 个表面暴露的丝氨酸(S)残基中的每一个都突变为缬氨酸(V)残基,其中三个突变体 S458V、S492V 和 S662V 的转导效率在不同的细胞类型中提高了约 20 倍。S662V 突变体有效地转导人单核细胞衍生的树突状细胞(moDC),而这种细胞类型不易被传统的 AAV 载体转导,并且不会在这些细胞中引起任何表型变化。生成了编码截短的人端粒酶(hTERT)基因的重组 S662V-AAV2 载体,并用于刺激针对靶细胞的细胞毒性 T 细胞(CTL)。S662V-AAV2-hTERT 载体转导的 DC 导致 T 细胞克隆迅速、特异性增殖,并产生强大的 CTL,从而导致 K562 细胞的特异性细胞裂解。这些研究表明,通过丝氨酸修饰的 AAV2 载体对 moDC 的高效转导是可行的,这支持了这些载体在未来人类 DC 疫苗研究中的潜在应用。